Bayer wins approval for a new blood thinner to prevent repeat strokes

Bayer's new type of blood thinner was approved on Monday, November 9, according to the report. Blood thinners reduce clot formation but can also increase bleeding risk. Added to existing blood thinners, Bayer's drug reduced the risk of repeat strokes in testing without significantly increasing bleeding risk.^[1]

The report does not identify the drug, the approving regulator or a launch date.^[1]

Bleeding risk influences whether doctors intensify treatment to prevent clots. These trial results could make doctors more willing to add Bayer's drug for suitable patients, creating additional prescription demand; no significant increase in bleeding does not mean the treatment carries no bleeding risk.^[1]

Turning that opportunity into revenue will depend on availability, price and insurance coverage. The report supplies none of those details, leaving the size of the sales opportunity unclear.^[1]

Impact